Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

2023393 citationsJournal Articlegreen Open Access

Authors

Gerald W. Prager · Université Paris Cité

Julien Taı̈eb · Université Paris Cité

Marwan Fakih · Université Paris Cité

Fortunato Ciardiello · University of Campania "Luigi Vanvitelli"

Eric Van Cutsem · Université Paris Cité

Élena Elez · Université Paris Cité

Felipe Melo Cruz ·

Abstract

Among patients with refractory metastatic colorectal cancer, treatment with FTD-TPI plus bevacizumab resulted in longer overall survival than FTD-TPI alone. (Funded by Servier and Taiho Oncology; SUNLIGHT ClinicalTrials.gov number, NCT04737187; EudraCT number, 2020-001976-14.).

Topics & Keywords

Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology Hepatocellular Carcinoma Treatment and Prognosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 388, Issue 18, pp. 1657-1667

DOI: 10.1056/nejmoa2214963

Field-Weighted Citation Impact: 94.41